FDA review risk classification of absorbable haemostatic devices:
This article was originally published in Clinica
Executive Summary
The US FDA is proposing to down-classify absorbable haemostatic devices intended to staunch blood flow during surgery. These products are currently class III devices, requiring clinical trials, but have been on the market for several years and are now considered safe enough to move to class II, the agency announced on October 31. This will allow companies to file a 510(k) without studying their device in humans if they follow the premarket advice of a new proposed guidance document released on the same date. Comments are due by January 27.
You may also be interested in...
EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications
Based on their experience with dealing with requests for access to documents over the past 12 years, EU regulators have proposed updating their guideline that provides for a harmonized approach to protecting personal data and business secrets in marketing authorization applications.
Industry & Regulators To Align Advice on COVID-19 Vaccine Updates
A multi-stakeholder workshop looked at the data needed to support updates to vaccine composition and the time required by manufacturers to update their vaccines, change their manufacturing processes and prepare approval applications.
Sanofi Skates To Where The Puck Is With Immunology
The French drugmaker has not abandoned oncology but has made it very clear that immunology and inflammation is the priority for its R&D euros.